BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10
BRIEF-Arcus Biosciences Says Dosed First Subject In ARC-10
March 16 (Reuters) - Arcus Biosciences Inc :
* ARCUS BIOSCIENCES INC - HAS DOSED FIRST SUBJECT IN ARC-10, A PHASE 3 STUDY
* ARCUS BIOSCIENCES - DOSING OF FIRST SUBJECT TRIGGERS MILESTONE PAYMENTS TO WUXI BIOLOGICS OF $10 MILLION AND ABMUNO THERAPEUTICS OF $5 MILLION
* ARCUS BIOSCIENCES INC - WILL OWE A SUBSEQUENT MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 TRIAL IN A SECOND INDICATION
Source text: () Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月16日电-Arcus Biosciences Inc:*Arcus Biosciences Inc-已经在ARC-10中给第一个受试者剂量,这是一项第三阶段的研究*Arcus Biosciences-第一个受试者的剂量触发向药明生物和ABMUNO治疗公司分别支付1,000万美元和500万美元的里程碑式付款*Arcus Biosciences Inc-在第二个适应症中启动3期试验后,将欠下一笔里程碑式的付款源文本:()进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。